URIGEN AND KALIUM SIGN CLINICAL STAGE LICENSING AGREEMENT

Urigen Holdings Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative products for urology indications and Kalium Inc., a California-based boutique drug development company, today announced that Urigen has licensed Kalium's patents and technology for the use of suppositories to deliver drug therapies to treat diseases of the genitourinary tract.

CNW Group (http://www.newswire.ca/en/releases/archive/May2006/22/c0742.html)